Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Palo Alto (17 mi)Age: Any Age
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Waitlist Available
Sponsor: Chimerix
No Placebo Group
Trial Summary
What is the purpose of this trial?This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.
Eligibility Criteria
Treatment Details
Find a clinic near you
Research locations nearbySelect from list below to view details:
Providence Neurological Specialties ClinicPortland, OR
Children's Healthcare of Atlanta, Emory University School of MedicineAtlanta, GA
New York UniversityNew York, NY
University of MichiganAnn Arbor, MI
More Trial Locations
Loading ...
Who is running the clinical trial?
ChimerixLead Sponsor